The results showed that AS-IV dose-dependently inhibited the proliferation of CRC cells and suppressed tumor growth, activated the levels of Caspase-3/7/9, Bax, inhibited the expression of Bcl-2, and promoted the cell cycle arrest at G0 phase (Sun et al., 2019). This evidence concerns the gene BCL2 and colorectal carcinoma.